ClinicalTrials.gg
RecruitingNCT07143201MIPD-PDAUpdated Aug 27, 2025

Precision Dosing of Oral Ibuprofen for PDA, A Pilot RCT

A Phase 2 interventional study of Standard Dose - Ibuprofen oral suspension and Precision Dose - Ibuprofen oral suspension in Patent Ductus Arteriosus and Preterm, sponsored by Hamilton Health Sciences Corporation. Recruiting at 1 site in Canada. Open to participants aged Up to 28 Weeks. Per ClinicalTrials.gov, last updated 2025-08-27.

Sponsored by Hamilton Health Sciences Corporation · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2026, 4 months ago, but the record still lists the study as recruiting.
  • Registered 1 year 1 month after the study started (first participant enrolled Jul 2024, registered Aug 2025).
  • Started Jul 2024; still recruiting 2 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
26
Allocation
Randomized
Ages
Up to 28 Weeks
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 10 studies in Ductus Arteriosus, Patent with a site in Canada — 6 open to participants now, 6 under way, 1 of them phase 3. Ductus Arteriosus, Patent · Canada.

Started
2024
the only one that year
Phase 2
2 of 10
2 open now
Registered
10th of 10
by date
Lead sponsor
1 of 10
Hamilton Health Sciences Corporation

Among the 10 studies in Ductus Arteriosus, Patent with a site in Canada, this one is the only one that started in 2024, is one of 2 in phase 2, and was the 10th registered.

Ductus Arteriosus, Patent

146 studies on the registry are indexed under Ductus Arteriosus, Patent; 21 are open to participants now.

Browse Ductus Arteriosus, Patent studies →

Open to participants now

6 of the 10 studies in Ductus Arteriosus, Patent with a site in Canada are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 14 Ductus Arteriosus, Patent studies recruiting now, 4 (29%) set no upper age limit and 10 (71%) stop at 75 or younger; 14 take children under 18; 1 takes healthy volunteers.

This study: Up to 28 Weeks · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Ductus Arteriosus, Patent with a site in Canada, or all of them as a file.
02

Study summary

Newborns born early are at risk for a serious health problem called patent ductus arteriosus (PDA). PDA is a passageway between heart and lung that can cause life-threatening complications such as bleeding in the brain or even death if it remains open and large. When closure of PDA is needed, doctors make every attempt to do it as soon as possible. Ibuprofen is the best drug to close the PDA, but it only works for 50% of small newborns. The investigators have shown before that small newborns handle ibuprofen differently and the amount of active ibuprofen that reaches their blood can be very unpredictable. Studies have shown if enough ibuprofen reaches the body, it can close the PDA. Therefore the investigators designed this study to see whether it is possible to give each newborn the right amount of ibuprofen that their body needs to close the PDA. The investigators will compare two ways to give ibuprofen in a small number of newborns: 1 - standard amount of ibuprofen to everyone, which is the usual care or 2 - ibuprofen doses that will be changed based on how much active ibuprofen has reached the body and how well the newborn's PDA is closing. The investigators will then compare the number of PDAs closed in each group and closely monitor any possible challenges for this new practice. By doing this project, the goals can be summarized as below:

A. Primary goal: To determine if it is feasible to successfully run a larger study in the future.

B. Secondary goals

  1. To assess how well and how safely the personalized (MIPD) method works, using a tool called WAPPS-PDA to guide dosing.
  2. To compare the effectiveness and safety of the personalized method with standard ibuprofen dosing.
  3. To identify drug levels in the blood (Cmin, AUC0-24, AUC0-72) that are associated with complete, partial, or no response to treatment.
Read the detailed description

Study Design Overview:

This clinical trial is a single-center, pilot, randomized, controlled, triple-blind study designed to evaluate the feasibility and effectiveness of model-informed precision dosing (MIPD) of oral ibuprofen compared to standard dosing for the treatment of Patent Ductus Arteriosus (PDA) in preterm neonates (≤27+6 weeks gestational age). The trial assesses both operational feasibility and clinical outcomes, with a focus on the use of a pharmacokinetic (PK) prediction module provided by the Web-Accessible Population Pharmacokinetics Service-PDA (WAPPS-PDA).

  • Standard Dosing Arm: Participants in this arm receive the standard oral ibuprofen regimen used in the unit. Treatment begins with an initial loading dose, followed by two smaller doses administered at 24-hour intervals. While PK samples and targeted echocardiograms are collected at the same intervals as in the precision dosing arm, these data points do not influence dosing decisions.
  • Model-Informed Precision Dosing (MIPD) Arm: Participants in this arm initially receive the same loading dose of ibuprofen as those in the standard dosing arm. Subsequent doses are adjusted using real-time PK data and echocardiographic evaluations through the WAPPS-PDA tool. This tool employs a Bayesian forecasting model to analyze blood samples collected at 6, 30, and 54 hours post-initial dose, combining these results with the PDA response level noted in the targeted echocardiograms to dynamically adjust dosing. Dose adjustments are reviewed every 12 hours to ensure tailored treatment based on the neonate's specific pharmacological response, optimizing the chances of effective PDA closure.
03

Conditions studied

  • Patent Ductus Arteriosus
  • Preterm

Keywords

  • MIPD-PDA
  • PDA
  • Precision Dosing
  • Ibuprofen
04

Who can participate

Ages eligible
Up to 28 Weeks
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Neonates with a gestational age of ≤27+6 weeks
  • Admitted to the neonatal intensive care unit (NICU) at McMaster Children's Hospital (MCH)
  • Diagnosed with PDA in need of treatment based on targeted neonatal echocardiography (TnEcho) performed prior to 27+6 CGA or postnatal age of 3 days, whichever comes later.
  • Obtained parental consent.

Exclusion criteria

Exclusion Criteria:

  • Major congenital or genetic abnormalities
  • Evidence for clinical or biochemical hepatic or renal failure ( > 225 U/L, ALT > 150 U/L, or serum creatinine > 130 µmol/L)
  • Sepsis - as defined by confirmed uncontrolled/active sepsis which will preclude any treatment of PDA
  • to receive oral ibuprofen:
  • Severe hyperbilirubinemia in need for exchange transfusion
  • Severe feeding intolerance
  • Necrotizing enterocolitis (NEC)
  • Gastrointestinal perforation
  • Active bleeding
  • Severe thrombocytopenia (\< 50× 109/L)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Care provider, Outcomes assessor)
Enrollment
26 participants (estimated)

Study arms

  • Active comparator
    Standard Dosing

    PNA-based standard dosing of ibuprofen \[ \<= 72 hours PNA: 10/5/5 q24hrs vs \>72 hours PNA 20/10/10 q24hrs\].

    Drug: Standard Dose - Ibuprofen oral suspension

  • Experimental
    Precision Dosing

    PNA-based regimen only for the initial dose, the rest of regimen will be guided by a MIPD, using a Web-Accessible Population Pharmacokinetics Service (WAPPS-PDA).

    Drug: Precision Dose - Ibuprofen oral suspension

Interventions

  • DrugIbuprofenStudies of IbuprofenIbuprofen pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Standard dosing administers ibuprofen without adjustments, starting with an initial loading dose followed by two maintenance doses at 24-hour intervals: 10/5/5 mg/kg for infants aged ≤72 hours, and 20/10/10 mg/kg for those \>72 hours old.

  • DrugPrecision Dose - Ibuprofen oral suspension

    Precision Dosing (Model-Informed Precision Dosing - MIPD): Begins with the same initial loading dose as the Standard Dosing arm, with subsequent doses adjusted based on a Bayesian forecasting model that integrates real-time PK and echocardiographic data.

06

What researchers measure

Primary outcomes

  1. Recruitment Feasibility

    Feasibility will be assessed by the ability to randomize at least 15% of all eligible patients during the study period.

    Time frame: From intial dose to 96 hours after.

  2. Timeliness of PK Sample Result Availability

    Feasibility will be assessed by the ability to obtain results for at least 80% of pharmacokinetic (PK) samples within 4 hours of sample collection.

    Time frame: From initial dose to 96 hours after

  3. Timeliness of Top-up Dosing Data for Intervention Arm

    Feasibility will be assessed by the ability to generate dosing data for top-up administration within 14 hours of the previous dose in at least 80% of subjects in the intervention arm.

    Time frame: From initial dose to 96 hours after

  4. Timely Completion of Daily Targeted Neonatal Echocardiogram (TnEcho)

    Feasibility will be assessed by the ability to perform daily TnEcho within 4 to 8 hours prior to the next scheduled dose in at least 80% of subjects.

    Time frame: From initial dose to 96 hours after

  5. Timely TnEcho Scoring and Model-Informed Precision Dosing (MIPD) Recommendation

    Feasibility will be assessed by the ability to score the TnEcho, assign responsiveness grouping, and provide the MIPD recommendation for the second and third doses of oral ibuprofen within 24 hours of the previous dose in at least 80% of subjects.

    Time frame: From initial dose to 96 hours after

Secondary outcomes

  1. Achievement of Target Trough Concentration and AUC (Intervention Arm Only)

    This exploratory outcome will evaluate the proportion of participants in the intervention arm who reach the predefined target trough concentration, AUC₀-₂₄, and AUC₀-₇₂. Results will be summarized descriptively and compared within the intervention group.

    Time frame: From first dose to 72 hours

  2. Maximum Ibuprofen Concentration (Cmax) ≤80 µg/mL (Intervention Arm Only)

    This outcome will assess the proportion of intervention-arm participants whose maximum ibuprofen concentration (Cmax) remains at or below the predefined limit of 80 µg/mL. Results will be described and compared to the predefined threshold.

    Time frame: From first dose to 72 hours

  3. Daily Ibuprofen Dose ≤40 mg/kg (Intervention Arm Only)

    This outcome will evaluate the proportion of participants in the intervention arm whose daily ibuprofen dose does not exceed 40 mg/kg. The frequency of participants meeting this dosing threshold will be summarized descriptively.

    Time frame: From first dose to 72 hours

  4. Closure of the Patent Ductus Arteriosus (PDA)

    This outcome will assess the proportion of participants with echocardiographically confirmed closure of the PDA following treatment. Results will be summarized and compared across study groups.

    Time frame: From first dose to 14 days

  5. Need for Repeat Pharmacotherapy

    This outcome will evaluate the proportion of participants requiring a repeat course of pharmacologic PDA treatment within 14 days of completing the initial course. Findings will be reported descriptively.

    Time frame: From first dose to 14 Days

  6. Need for Surgical Ligation

    This outcome will assess the proportion of participants who require surgical ligation of the PDA due to persistent patency or clinical deterioration. Results will be summarized for both study groups.

    Time frame: From first dose to 14 Days

  7. Treatment Interruption

    This outcome will describe the proportion of participants whose ibuprofen treatment was interrupted prior to completion due to clinical or safety concerns. Outcomes will be compared descriptively.

    Time frame: From first dose to 14 Days

  8. Occurrence of Adverse Events

    This outcome will describe the proportion of participants who experience at least one adverse event during the follow-up period. Events will be classified by severity and relatedness to the study drug, and summarized descriptively.

    Time frame: From first dose to 14 Days

07

Study locations

1 of 1 sites recruiting
  • McMaster Children's Hospital - Neonatal Intensive Care Unit
    Hamilton, Ontario L8N 3Z2, Canada
    Recruiting
    • Samira Samiee-Zafarghandy, MD, FRCPC · Contactsamiees@mcmaster.ca · 1-905-521-2100
    • Heather Johnson, BScN · Contactjohnsh30@mcmaster.ca
    • Samira Samiee-Zafarghandy, MD, FRCPC · Principal investigator
08

References and documents

Publications

  • McEneny-King A, Foster G, Iorio A, Edginton AN. Data Analysis Protocol for the Development and Evaluation of Population Pharmacokinetic Models for Incorporation Into the Web-Accessible Population Pharmacokinetic Service - Hemophilia (WAPPS-Hemo). JMIR Res Protoc. 2016 Dec 7;5(4):e232. doi: 10.2196/resprot.6559. PubMed 27927609 ↗
  • Euteneuer JC, Kamatkar S, Fukuda T, Vinks AA, Akinbi HT. Suggestions for Model-Informed Precision Dosing to Optimize Neonatal Drug Therapy. J Clin Pharmacol. 2019 Feb;59(2):168-176. doi: 10.1002/jcph.1315. Epub 2018 Sep 11. PubMed 30204236 ↗
  • Van Overmeire B, Touw D, Schepens PJ, Kearns GL, van den Anker JN. Ibuprofen pharmacokinetics in preterm infants with patent ductus arteriosus. Clin Pharmacol Ther. 2001 Oct;70(4):336-43. PubMed 11673749 ↗
  • Hirt D, Van Overmeire B, Treluyer JM, Langhendries JP, Marguglio A, Eisinger MJ, Schepens P, Urien S. An optimized ibuprofen dosing scheme for preterm neonates with patent ductus arteriosus, based on a population pharmacokinetic and pharmacodynamic study. Br J Clin Pharmacol. 2008 May;65(5):629-36. doi: 10.1111/j.1365-2125.2008.03118.x. Epub 2008 Feb 27. PubMed 18307541 ↗
  • Engbers AGJ, Voller S, Flint RB, Goulooze SC, de Klerk J, Krekels EHJ, van Dijk M, Willemsen SP, Reiss IKM, Knibbe CAJ, Simons SHP. The Effect of Ibuprofen Exposure and Patient Characteristics on the Closure of the Patent Ductus Arteriosus in Preterm Infants. Clin Pharmacol Ther. 2022 Aug;112(2):307-315. doi: 10.1002/cpt.2616. Epub 2022 May 6. PubMed 35429165 ↗
  • Barzilay B, Youngster I, Batash D, Keidar R, Baram S, Goldman M, Berkovitch M, Heyman E. Pharmacokinetics of oral ibuprofen for patent ductus arteriosus closure in preterm infants. Arch Dis Child Fetal Neonatal Ed. 2012 Mar;97(2):F116-9. doi: 10.1136/adc.2011.215160. Epub 2011 Aug 11. PubMed 21840880 ↗
  • Samiee-Zafarghandy S, van Donge T, Fusch G, Pfister M, Jacob G, Atkinson A, Rieder MJ, Smit C, Van Den Anker J. Novel strategy to personalise use of ibuprofen for closure of patent ductus arteriosus in preterm neonates. Arch Dis Child. 2022 Jan;107(1):86-91. doi: 10.1136/archdischild-2020-321381. Epub 2021 May 11. PubMed 33975823 ↗
  • Mitra S, Florez ID, Tamayo ME, Mbuagbaw L, Vanniyasingam T, Veroniki AA, Zea AM, Zhang Y, Sadeghirad B, Thabane L. Association of Placebo, Indomethacin, Ibuprofen, and Acetaminophen With Closure of Hemodynamically Significant Patent Ductus Arteriosus in Preterm Infants: A Systematic Review and Meta-analysis. JAMA. 2018 Mar 27;319(12):1221-1238. doi: 10.1001/jama.2018.1896. PubMed 29584842 ↗

Individual participant data

Plan to share: No — This is a pilot feasibility study with a small sample size, and there are no current plans for data sharing.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2024 (actual). Primary completion is estimated for Jul 2026, 24 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 8, 2025
First posted
Aug 27, 2025
StartActual
Jul 4, 2024
Primary completionEst.
Jul 2026
CompletionEst.
Jul 2027
Last update
Aug 27, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 27, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07143201
Collaborators
McMaster University, Hamilton Academic Health Sciences Organization
Responsible party
Samira Samiee-Zafarghandy (Principal Investigator, Hamilton Health Sciences Corporation) — Principal investigator
First posted
Aug 27, 2025
Start date
Jul 4, 2024
Primary completion
Jul 2026 (estimated)
Completion
Jul 2027 (estimated)
Last update
Aug 27, 2025

Study contacts

Samira Samiee-Zafarghandy, MD, FRCPC
Contact
samiees@mcmaster.ca
1-905-521-2100 ext. 73568
Samira Samiee-Zafarghandy, MD, FRCPC
principal investigator · McMaster University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion